The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
Alexion recalls some Soliris batches
November 13, 2013
7:17 pm
The US-only recall amounts to less than 1% of the company’s inventory.
FDA delays Sarepta MD drug
November 12, 2013
7:26 pm
The regulator says the drugmaker needs to do more testing.
Shire, Salix buy way to expansion
November 11, 2013
7:12 pm
The companies are plunking down substantial sums to increase their reach.
Price, market potential and emotional pull make this subcategory of orphan diseases one to watch, an analyst writes. Hint: it’s not oncology.
Business briefs: Takeda, Sangamo, Catalyst, plus seniors and insurance
August 28, 2013
5:44 pm
Takeda moves an Alzheimer’s treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance
Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire
August 26, 2013
5:43 pm
Australia’s price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn’s trial; and Shire extends Santaris rare-disease collaboration